best telehealth weight loss program glp-1 prescriptions 2025 Personalized and affordable plan The Best and Cheapest Online
Description
The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course
#ASCO #PublicHealth #WomenInMedicine #DiabetesCare #CancerResearch
GLP-1 RAs reduce gut motility by slowing gastric emptying and altering the migrating motor complex (MMC), increasing the risk of conditions like gastroparesis and bowel obstruction
Experience powerful dual-action weight loss with Tirzepatide
Learn what researchers discovered, why the findings matter, and key reminders for people with type 2 diabetes concerned about brain health.
Learn why Bioidentical Hormone Replacement and GLP-1 Medications Work Together for Perimenopausal and Menopausal Women.
